Time for a reassessment of the use of Kava in anxiety?

Complementary Therapies in Medicine

Volumn 17, Issue 3, 2009, Pages 121-122

  Sarris, J ^a   Adams, J ^a   Wardle, J L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; DIHYDROMETHYSTICIN; KAVA EXTRACT; KAVALACTONE DERIVATIVE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANXIETY DISORDER; DRUG ABUSE; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; EDITORIAL; HUMAN; LIVER TOXICITY; QUALITY CONTROL; TRADITIONAL MEDICINE; TRANQUILIZING ACTIVITY;

AGRICULTURE; ANXIETY; CANADA; DRUG AND NARCOTIC CONTROL; EUROPEAN UNION; GREAT BRITAIN; HUMANS; KAVA; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 65049085570     PISSN: 09652299     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctim.2009.01.003     Document Type: Editorial

References (9)

1. Coulter D. Assessment of the risk of hepatotoxicity with Kava products. WHO appointed committee (2007), World Health Organisation, Geneva
2. Kava R. The adverse effects of kava. Pacific Health Dialog 8 1 (2001) 115-118
3. Moulds R., and Malani J. Kava: herbal panacea or liver poison?. Medical Journal of Australia 178 9 (2003) 451-453
4. Jowitt A., and Binihi J. The commercialisation of Kava in Vanuatu. Pacific Health Dialog 8 1 (2001) 29-37
5. Sofer M. Yaqona and the Fijian periphery revisited. Asia Pacific Viewpoint 48 2 (2007) 234-249
6. Pittler M.H., and Ernst E. Kava extract for treating anxiety. Cochrane Database Systematic Review 1 (2003) CD003383
7. Schmidt M. The German 'Ban' on Kava imports: recent developments. HerbalGram 5 12 (2008)
8. Lebot V. The quality of Kava consumed in the South Pacific. HerbalGram 71 (2006) 34-37
9. Gruenwald J., Mueller C., and Skrabal J. In depth investigation on EU member states market restrictions on Kava products (2003), Centre for the Development of Enterprise, Brussels